When you pee, you can easily know when you eat something specific, like asparagus. It was also by smelling urine that antic physicians could determine diabetes disease. We know urine can contain compounds specifics of food and disease. But it is complicated to determine which ones are specific to a particular disease. Therefore, we use advanced analytical techniques to analyze the urine and determine which compounds, the metabolites, are biomarkers of a disease. In the COLOVOC project, we analyze both the smell (volatiles) and the ‘flavor’ (liquid) of urine with mass spectrometry techniques. We have the aim of determining which metabolites are specific of colorectal cancer (CRC). Colorectal cancer (CRC) is the second most frequent neoplasia, after breast cancer in women and lung cancer in men. It is the most malignant digestive neoplasia in the western world, with a higher incidence than all other tumours combined. It is estimated that in a standard population, compliance with CRC screening is only ~30-50%. The main aim of the COLOVOC project is to identify new biomarkers and/or validate proposed ones and explore colorectal cancer diagnosis using metabolites found in urine. With a long-term aim to improve the CRC screening programs and reduce the burden of the health systems widely affected by the pandemic.